Hormon replasman tedavisinin kardiyak fonksiyonlar üzerine etkisinin yeni parametrelerle değerlendirilmesi

Amaç: Menopoz nedeniyle meydana gelen değişikliklerden en çok etkilenen sistemlerden biri de kardiyovasküler sistemdir. Bu çalışma, sağlıklı postmenopozal kadınlarda HRT´nin kardiyak fonksiyonlar üzerine etkilerinin yeni parametreler kullanılarak değerlendirilmesi amacıyla planlanmıştır. Yöntem: Çalışmaya HRT uygulanacak 35 ve kontrol grubu olarak da aynı özelliklere sahip 32 sağlıklı postmenopozal kadın alındı. Tüm bireylere standart ekokardiyografi yapıldı. Ardından doku Doppler pulsed wave yöntemi uygulanarak miyokardiyal hızlar ile sistolik ve diyastolik zaman intervalleri ölçülerek miyokard performans indeksi (MPİ) hesaplandı. Üç ay sonra elde edilen parametreler, bazal değerlerle karşılaştırıldı. Bulgular: Sol ventrikül (SV) segmenter sistolik miyokardiyal hız (Sm), ortalama Sm ve triküspit Sm değerlerinde her iki grupta da 3 ay sonra değişiklik tespit edilemedi. HRT grubunda SV için ortalama erken miyokardiyal hızı (Em) artarken geç miyokardiyal hız (Am) azaldı. Em/Am oranı ve mitral erken diyastolik doluş hızı/mitral geç diyastolik hızı oranı arttı. MPİ değerlerinde HRT alan grupta üç ay sonra azalma eğilimi vardı. Fakat bu değişiklikler istatistiki anlamlılığa ulaşmadı. Sonuç: Anlamlı olmasa da, 3 ay süreli HRT özellikle SV diyastolik fonksiyonlarında düzelmeye neden olabilir. Bu düzelme eğiliminin anlamlı olup olmadığının ortaya çıkarılması için uzun süreli geniş katılımlı randomize çalışmalara ihtiyaç vardır.

Evaluation of the effect of hormone replacement therapy on cardiovascular functions with new parameters

Objective: Cardiovascular system is one of the most affected system in menopause. It is aimed to investigate the effects of HRT on cardiovascular functions in healthy postmenopausal women. Methods: Thirty-seven patients given HRT were taken as study group and 32 healthy postmenopausal women were taken as control group. Standard echocardiography were performed to all cases. Sequentially, systolic and diastolic time intervals were measured with pulsed wave tissue Doppler and myocardial performance index was calculated. The same parameters obtained after 3 months of HRT and compared with the basal values. Results: There was no change at left ventricle (LV) segmental systolic myocardial velocity (Sm) and tricuspid Sm values after 3 months according to basal values in both groups. While the mean early myocardial velocity (Em) of LV increased, late myocardial velocity (Am) decreased and Em/Am ratio increased in HRT group. In addition it was determined that the mitral early inflow velocity/late inflow velocity ratio increased. Mean LV myocardial performance index was also decreased after the 3 months of HRT. Nevertheless, these changes could not reach to a statistically significance. Conclusion: Although it is not significant, HRT may cause improvement in LV diastolic function. Long term, wide spectrum randomized studies are needed to expose whether this improvement trend will be significant or not.

___

  • 1. Ertungealp E, Seyisoğlu H. Klimakteryum ve menopoz. İçinde: Kisnişci, Gökşin editörler. Temel Kadın Hastalıkları ve Doğum Bilgisi. Ankara, Güneş Kitabevi, 1996; 1331-46.
  • 2. Gorodeski G, Ution WH. Epidemiology and risk factors of cardiovascular disease in postmenopausal women. In: Lobo RA, ed. Treatment of postmenopausal women. New York: Rawen Press; 1994. 12-32.
  • 3. Hendersen BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-18.
  • 4. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B. et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
  • 5. Stevenson JC. The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 1995;49:87-90.
  • 6. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002;89 (suppl): 12E- 18E.
  • 7. The Writing group for the PEPI trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopozal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273:199-208.
  • 8. Koh KK, Mincemoyer R, Bul MN, Csako G, Pucino F, Guetta V, et al. Effect of hormone replacement therapy on fibrinolysis in postmenopausal women. N Eng J Med 1997;336:693-690.
  • 9. Hulley S, Grady P, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopozal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
  • 10. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcome during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 2002;288:49-57.
  • 11. Writing group for the Women´s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopozal women. Principal results from the Women´s Health Initiative randomised controlled trial. JAMA 2002;288:321-33.
  • 12. Pines A, Fisman EZ, Shemesh J, Levo Y, Ayalon D, Kellermann JJ, et al. Menopause-related changes in left ventricular function in healthy women. Cardiology 1992; 80:413-6.
  • 13. Prelevic GM, Beljie T. The effect of estrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women. Maturitas 1994;20:37-44.
  • 14. Pines A, Fisman EZ, Levo Y, Drory D, Ben-Ari E, Motro M, et al. Menopause-induced changes in left ventricular wall thickness. Am J Cardiol 1993;72:240-1.
  • 15. Alan DW, Michelle B. Tissue doppler imaging: Useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function. J Am Soc Echocardiogr 2001;14:1143-52.
  • 16. Dağdelen S, Eren N, Karabulut H, Akdemir İ, Ergelen M, Akçay M. Sol ventrikül hipertrofisi ile diyastolik fonksiyonlar arasındaki ilişkinin yeni ekokardiyografik yaklaşımlarla değerlendirilmesi. Türk Kardiyoloji Derneği Arşiv 2001;29:173-80
  • 17. Cristopher.SH, Raymond PK, Peter C. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 2000;46:28-49.
  • 18. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
  • 19. Kuch B, Hense HW, Muscholl M. Postmenopausal hormone replacement therapy and left ventricular mass and geometry. J Am Coll Cardiol 1997; 29:297A.
  • 20. Fak AS, Erenus M, Tezcan H, Caymaz O, Oktay S, Oktay A. Effects of a single dose of oral estrogen on left ventricular diastolic function in hypertensive postmenopausal women with diastolic dysfunction. Fertil Steril 2000;3:66-71.
  • 21. Taşkın O, Gökdeniz R, Müderrisoğlu H, Korkmaz ME, Uryan I, Atmaca R, Kafkaslı A. The effects of hormone on echocardiographic basic cardiac functions in postmenopausal women. Hum Reprod 1998;13:2399-401.
  • 22. Yıldırır A, Yaralı H, Kabakçı G, Aybar F, Akgul E, Bukulmaz O. Hormone replacement therapy to improve left ventricular diastolic functions in healthy postmenopausal women. Intern J Gynecol Obstetr 2001;75:273-8.
  • 23. Özdemir K, Çelik Ç, Altunkeser BB, Içli A, Albeni H, Duzenli A, et al. Effect of postmenopausal hormone replacement therapy on cardiovascular performance. Maturitas 2004;47:107-13.
  • 24. Yılmaz R, Baykan M, Erdöl C. Pulsed wave Doppler echocardiyografi. Anadolu Kardiyoloji Derg 2003;3:54-60.
  • 25. Mercuro G, Zoncu S, Paoletti AM, Melis GB, Vacca AMB, Cherchi A. Study of myocardial contractility by pulsed wave Doppler tissue imaging does not reveal an inotropic effect of estrogen at physiologic dose. Am J Cardiol 1999;83:677-1679.
  • 26. Tei C. New noninvasive index for combined systolic and diastolic ventricular function. J Cardiol 1995;26:135-6.
  • 27. Terkan T, Onbaşılı A O, Ceyhan C, Ünal S, Ağaoğlu. Tissue Doppler Miyocardial Performance İndex (Doku Doppler Miyokard İndeksi). Türk Kardiyol Dern Araş 2003;31:262-9.
  • 28. Eto G, Ishii M, Tei C, Tsutsumi T, Akagi T, Kato H. Assessment of global left ventricular function in normal children and in children with dilated cardiomyopathy. J Am Soc Echocardiogr 1999;12:1058-64.
  • 29. Eidem BW, Sapp BG, Suare CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 2001;87:1020-2.
  • 30. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived MPI combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998;81:1157-61.
  • 31. Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. Prognostic value of a Doppler MPI combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 1998; 82:1071-6.